Sana to open new CGT manufacturing facility

By The Science Advisory Board staff writers

July 15, 2021 -- Sana Biotechnology has signed a lease to develop a 163,000-sq-ft manufacturing facility in Fremont, CA, to support the manufacture of its late-stage clinical development and early commercial cell and gene therapy (CGT) candidates.

The facility will be designed to provide manufacturing capabilities across the company's portfolio, including allogeneic T cell, viral vector, and pluripotent stem cell production.

The facility's location is in close proximity to Sana's existing technical and scientific capabilities, the firm said. Sana also intends to work with contract manufacturing partners to advance its candidates to the clinic as early as next year.


Copyright © 2021 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.